Loading...
Most individual studies of omega-3 fatty acids (FAs) — generally combinations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — have failed to show significant reductions in adverse cardiovascular (CV) events in primary and secondary prevention populations. Although omega-3 FA supplementation is not recommended strongly in U.S. guidelines, many patients continue to use them, and some clinicians recommend them. Three more negative randomized trials were published in late 2020.
In an international trial, 13,000 patients with known CV disease or high risk for CV disease received either 4 g daily of a carbolic acid formulation of EPA/DHA or corn oil placebo. At 42 months, a composite CV endpoint occurred in about 12% of each group,…